Evidence map›Paper›PMID 40837758›Full record

ArticleWorld journal of gastrointestinal oncology2025

Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China.

Hansoo Kim, Joshua Byrnes, Kui-Rong Jiang, Zhuan Liao, Arun Jones, Kyoo Kim, Dafni Fragkogianni, Keith J Roberts

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hansoo KimHealth Economics Group, Griffith University, Gold Coast QLD4215, Queensland, Australia.
Joshua ByrnesHealth Economics Group, Griffith University, Gold Coast QLD4215, Queensland, Australia.
Kui-Rong JiangDepartment of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China.
Zhuan LiaoShanghai Institute of Pancreatic Diseases, Shanghai 201613, China.
Arun JonesHealth Economics Group, Griffith University, Gold Coast QLD4215, Queensland, Australia. arun.jones@griffith.edu.au.
Kyoo KimAbbott Products Operations AG, Hegenheimermattweg 127, 4123 Allschwil, Switzerland.
Dafni FragkogianniAbbott Products Operations AG, Hegenheimermattweg 127, 4123 Allschwil, Switzerland.
Keith J RobertsDepartment of HBP and Liver Transplantation Surgery, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham B15 2GW, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic exocrine insufficiency (PEI) leads to fat malabsorption and maldigestion and is most commonly treated with pancreatic enzyme replacement therapy (PERT). Patients suffering from PEI in China are more likely not to receive adequate treatment as this drug is not part of the Chinese national essential medicine list.

aimTo examine the cost-effectiveness of PERT for patients suffering from PEI in China.

methodsA decision analytical Markov model was constructed to simulate the progress of patients with PEI in China. The population included in the analyses were patients suffering from PEI with advanced (non-resectable) pancreatic cancer, who have undergone surgery due to pancreatic cancer and who have undergone endoscopic treatment due to chronic pancreatitis. The cost-effectiveness analyses were undertaken from a Chinese societal perspective comparing PERT with no PERT. The incremental cost-effectiveness ratio in United States dollars

resultsThe cost-effectiveness analyses estimated that PERT resulted in additional 0.45 to 2.93 QALYs at discounted costs of between 4315 dollars to 15193 dollars. This resulted in an incremental cost-effectiveness ratio of 5178 dollars to 9533 dollars

conclusionThis study demonstrates that PERT is a cost-effective treatment for patients suffering from PEI in China.

Indexed as

ChinaCost-effectiveness analysisNational essential medicine listPancreatic enzyme replacement therapyPancreatic exocrine insufficiency

Identifiers

PMID40837758
PMCPMC12362560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.